Andrea Moore

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

David P. Dearnaley, Matthew R. Sydes, John D. Graham et al. · The Lancet Oncology · 2007 · 904 citations

Radiation Therapy, Medicine, Mrc Rt01 +8

Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received

David E. Neal, Chris Metcalfe, Jenny Donovan et al. · European Urology · 2019 · 147 citations · Full text

Dose–Volume Constraints to Reduce Rectal Side Effects From Prostate Radiotherapy: Evidence From MRC RT01 Trial ISRCTN 47772397

S. Gulliford, Kerwyn Foo, Rachel C. Morgan et al. · International Journal of Radiation Oncology*Biology*Physics · 2009 · 131 citations · Full text

Urology, Radiation Medicine, Radiation Therapy +6

Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer

Oliver Sartor, M. Weinberger, Andrea Moore et al. · Urology · 1998 · 94 citations

Urology, Genitourinary Cancer, Medicine +6

Questionnaire based quality assurance for the RT01 trial of dose escalation in conformal radiotherapy for prostate cancer (ISRCTN 47772397)

W. P. M. Mayles, Andrea Moore, Edwin Aird et al. · Radiotherapy and Oncology · 2004 · 22 citations

Reliability, Quality Assurance, Radiation Therapy +8